Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT)
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updatesâread...
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Phathom Pharma (PHAT) Q2 2026 earnings call: VOQUEZNA growth, first operating profit, lower revenue guidance on payer friction, and pipeline updatesâread...
Phathom forecasts $310M-$325M 2026 revenue while planning Phase 3 as-needed GERD trial in Q4 (NASDAQ:PHAT) | Seeking Alpha
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2026
Management View
"For the first time in Phathom's history and ahead of our guidance, we generated positive operating profit in Q2, excluding stock-based compensation." (CEO, President & Director Steven Basta)
"For full
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Quick Insights
What are the key risks to Phathom Pharmaceuticals' VOQUEZNA revenue growth?
The main risks are physician and payer friction limiting prescribing, competitive uncertainty from new entrants, and possible hesitation due to perceived hurdles despite operational efforts to streamline workflows.
How is Phathom Pharmaceuticals addressing physician and payer workflow friction for VOQUEZNA?
Phathom is focused on incremental efficiency improvements, leveraging omnichannel investment, streamlining prior authorization with Blink support, and supporting high prescribers, as well as highlighting coverage and operational enhancements.
What is the financial outlook and profitability trajectory for Phathom Pharmaceuticals?
Phathom updated its revenue guidance to $310-$325 million for the year, achieved its first operating profit (excluding stock-based compensation) ahead of schedule, expects sustained profitability, and aims for durable cash flow positivity in 2027, while OpEx guidance incorporates planned pipeline investments.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
HNI projects 20%-25% non-GAAP EPS growth in 2026 as Steelcase synergies target rises to at least $120M (NYSE:HNI)
HNI (HNI) Q2 2026 earnings call recap: non-GAAP EPS $1.27, raised 2026 outlook to 20â25% growth, Steelcase synergies â¥$120M.
Euronet reiterates 10% to 15% full-year adjusted EPS growth as digital accelerators rise 35% YTD (NASDAQ:EEFT)
Euronet (EEFT) Q2 2026 earnings call recap: EPS +10%, digital accelerators +31%, CoreCard wins, and outlook intact.
NPK International raises 2026 adjusted EBITDA outlook to $97M-$103M while keeping mid-2027 Louisiana expansion start-up date (NYSE:NPKI)
NPKI Q2 2026 earnings call highlights: record rental/service revenue, strong product sales, and raised EBITDA guidance.
Live Nation Beats Quarterly Estimates as Concert Demand Drives Growth
Live Nation Entertainment reported quarterly revenue and profit that exceeded Wall Street expectations, fueled by strong concert ticket sales and the ongoing experiential spending trend. Analysts remain optimistic about growth prospects but caution about competition and regulatory risks.
